Research
Energy balance
By 2025, GLP-1RAs are anticipated to receive FDA approval for new indications including chronic kidney disease and heart failure.
Healthcare providers should stay informed about upcoming indications for GLP-1RAs to optimize treatment options.
GoodSupportsmedium confidence
By 2025, GLP-1RAs are anticipated to receive FDA approval for new indications, such as chronic kidney disease, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatohepatitis.
Why this rating
The claim is based on projections discussed in the review.
Source
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Riad Mohammed Abdelrahman et al. · Journal of Obesity · 2025
DOI 10.1155/jobe/9919810
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.Strong
- The integration of digital health and artificial intelligence is expected to advance antiobesity drug development.Moderate
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →